MORGAN STANLEY PLC/CALL/BIOGEN IDEC/280/0.01/20.09.24 | Real-time Bid/Ask 05:30:51 2024-07-12 am EDT | ||
| 0.036 EUR / 0.046 EUR | +20.59% |
|
| Current month | -2.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.035 | +2.94% |
| 24-07-11 | 0.034 | +9.68% |
| 24-07-10 | 0.031 | +3.33% |
| 24-07-09 | 0.03 | +3.45% |
| 24-07-08 | 0.029 | +7.41% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 03:37 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MG6CDK |
| ISIN | DE000MG6CDK3 |
| Date issued | 2024-06-20 |
| Strike | 280 $ |
| Maturity | 2024-09-20 (71 Days) |
| Parity | 100 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.041 € |
|---|---|
| Lowest since issue | 0.025 € |
| Spread | 0.01 € |
| Spread % | 21.74% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
236.8
USD
Average target price
281.3
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- Warrant
